FibroBiologics (FBLG) EBT (2023 - 2026)

FibroBiologics (FBLG) has reported EBT for 4 consecutive years, with -$4.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 9.35% year-over-year to -$4.0 million; the trailing twelve-month figure through Jun 2026 stood at -$16.8 million (down 6.37% YoY), and the FY2025 full-year result was -$16.6 million, down 22.95% from the prior year.
• EBT grew to -$4.0 million in Q2 2026 per FBLG's latest filing, from -$5.1 million in the prior quarter.
• Across five years, EBT topped out at -$2.1 million in Q3 2023 and bottomed at -$5.1 million in Q1 2026.
• Historically, EBT has averaged -$3.4 million across 4 years, with a median of -$3.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: EBT sank 59.75% in 2024, then grew 24.24% in 2025.
• Over 4 years, EBT stood at -$2.5 million in 2023, then tumbled by 47.32% to -$3.7 million in 2024, then gained by 24.24% to -$2.8 million in 2025, then tumbled by 45.36% to -$4.0 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$4.0 million, -$5.1 million, and -$2.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.